File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: Importance of tumor biomarker in ablative therapies

TitleHigh serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: Importance of tumor biomarker in ablative therapies
Authors
KeywordsHepatocellular carcinoma
Radiofrequency ablation
Tumor biomarker
Vascular endothelial growth factor
Issue Date2007
PublisherSpringer New York LLC. The Journal's web site is located at http://www.annalssurgicaloncology.org
Citation
Annals Of Surgical Oncology, 2007, v. 14 n. 6, p. 1835-1845 How to Cite?
AbstractBackground: Radiofrequency ablation (RFA) is a recently developed treatment for hepatocellular carcinoma (HCC). Thus far, the prognostic impact of tumor biomarkers has not been evaluated in this treatment. High serum level of vascular endothelial growth factor (VEGF) has been shown to predict microscopic vascular invasion and metastasis in HCC. This study investigated the prognostic significance of pre-treatment serum VEGF level in patients with HCC undergoing RFA treatment. Methods: Serum VEGF levels were measured using enzyme-linked immunosorbent assay in 120 patients with HCC undergoing RFA, and in 15 healthy controls. Serum VEGF levels were correlated with clinicopathological features of the HCC patients. The prognostic significance of serum VEGF levels was assessed by univariate and multivariate analyses. Results: The median serum VEGF level in the HCC patients was 240 pg/mL (range 17-1162), significantly higher than that of healthy controls (p = .024). The serum VEGF levels were significantly correlated with platelet counts (r = .487, p < .001) but not other clinicopathological features. Patients with serum VEGF level > 240 pg/mL had worse overall and recurrence-free survival compared with those with serum VEGF level > 240 pg/mL (p = .005 and .002, respectively). By multivariate analysis, serum VEGF level was a significant prognostic factor of both overall and recurrence-free survival. Conclusions: High pre-treatment serum VEGF levels predict poor prognosis after RFA of HCC. This study highlights the importance of tumor biomarker as a prognostic predictor in ablative therapy for HCC, which has an intrinsic problem of unavailability of histopathological prognostic features. © 2007 Society of Surgical Oncology.
Persistent Identifierhttp://hdl.handle.net/10722/71902
ISSN
2014 Impact Factor: 3.930
2014 SCImago Journal Rankings: 1.812
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorPoon, RTPen_HK
dc.contributor.authorLau, Cen_HK
dc.contributor.authorPang, Ren_HK
dc.contributor.authorNg, KKen_HK
dc.contributor.authorYuen, Jen_HK
dc.contributor.authorFan, STen_HK
dc.date.accessioned2010-09-06T06:36:18Z-
dc.date.available2010-09-06T06:36:18Z-
dc.date.issued2007en_HK
dc.identifier.citationAnnals Of Surgical Oncology, 2007, v. 14 n. 6, p. 1835-1845en_HK
dc.identifier.issn1068-9265en_HK
dc.identifier.urihttp://hdl.handle.net/10722/71902-
dc.description.abstractBackground: Radiofrequency ablation (RFA) is a recently developed treatment for hepatocellular carcinoma (HCC). Thus far, the prognostic impact of tumor biomarkers has not been evaluated in this treatment. High serum level of vascular endothelial growth factor (VEGF) has been shown to predict microscopic vascular invasion and metastasis in HCC. This study investigated the prognostic significance of pre-treatment serum VEGF level in patients with HCC undergoing RFA treatment. Methods: Serum VEGF levels were measured using enzyme-linked immunosorbent assay in 120 patients with HCC undergoing RFA, and in 15 healthy controls. Serum VEGF levels were correlated with clinicopathological features of the HCC patients. The prognostic significance of serum VEGF levels was assessed by univariate and multivariate analyses. Results: The median serum VEGF level in the HCC patients was 240 pg/mL (range 17-1162), significantly higher than that of healthy controls (p = .024). The serum VEGF levels were significantly correlated with platelet counts (r = .487, p < .001) but not other clinicopathological features. Patients with serum VEGF level > 240 pg/mL had worse overall and recurrence-free survival compared with those with serum VEGF level > 240 pg/mL (p = .005 and .002, respectively). By multivariate analysis, serum VEGF level was a significant prognostic factor of both overall and recurrence-free survival. Conclusions: High pre-treatment serum VEGF levels predict poor prognosis after RFA of HCC. This study highlights the importance of tumor biomarker as a prognostic predictor in ablative therapy for HCC, which has an intrinsic problem of unavailability of histopathological prognostic features. © 2007 Society of Surgical Oncology.en_HK
dc.languageengen_HK
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.annalssurgicaloncology.orgen_HK
dc.relation.ispartofAnnals of Surgical Oncologyen_HK
dc.rightsThe original publication is available at www.springerlink.com-
dc.subjectHepatocellular carcinomaen_HK
dc.subjectRadiofrequency ablationen_HK
dc.subjectTumor biomarkeren_HK
dc.subjectVascular endothelial growth factoren_HK
dc.subject.meshCarcinoma, Hepatocellular - blood - surgery-
dc.subject.meshCatheter Ablation-
dc.subject.meshLiver Neoplasms - blood - surgery-
dc.subject.meshTumor Markers, Biological - blood-
dc.subject.meshVascular Endothelial Growth Factor A - blood-
dc.titleHigh serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: Importance of tumor biomarker in ablative therapiesen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1068-9265&volume=14&issue=6&spage=1835&epage=1845&date=2007&atitle=High+serum+vascular+endothelial+growth+factor+levels+predict+poor+prognosis+after+radiofrequency+ablation+of+hepatocellular+carcinoma:+importance+of+tumor+biomarker+in+ablative+therapiesen_HK
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hken_HK
dc.identifier.emailPang, R: robertap@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.identifier.authorityPang, R=rp00274en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1245/s10434-007-9366-zen_HK
dc.identifier.pmid17406950-
dc.identifier.scopuseid_2-s2.0-34249900712en_HK
dc.identifier.hkuros137545en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-34249900712&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume14en_HK
dc.identifier.issue6en_HK
dc.identifier.spage1835en_HK
dc.identifier.epage1845en_HK
dc.identifier.isiWOS:000247470300009-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridPoon, RTP=7103097223en_HK
dc.identifier.scopusauthoridLau, C=8086563300en_HK
dc.identifier.scopusauthoridPang, R=7004376659en_HK
dc.identifier.scopusauthoridNg, KK=7403179075en_HK
dc.identifier.scopusauthoridYuen, J=7102620431en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats